Beximco Pharma enters EU Market, starting its Export to Germany and Austria
Beximco Pharmaceuticals Limited has commenced export of medicines to Europe. This is the first time, a local pharma company exported ophthalmic products to Europe. A signing ceremony was held on the factory premises of Beximco Pharma to mark the first consignment to Europe in presence of high officials of the company and representatives from DHL and Emirates.
Initially, two ophthalmic products—Latanoprost and a combination of Latanoprost and Timolol—will be exported to Germany and Austria with other EU countries to follow. Latanoprost and Timolol are used to reduce the pressure inside the eye for people with open-angle glaucoma or intraocular hypertension (increased pressure in the eye). Beximco Pharma expects to launch additional new products in the EU later this year. Speaking on the occasion, Managing Director of Beximco Pharma Nazmul Hassan, MP, says: “Beximco has established a presence in a growing number of markets around the world. The Company is increasingly focused on penetrating large and highly regulated markets such as the EU and US, where the demand for generic products continues to rise.” He said Beximco has developed high quality pharmaceutical facilities in Bangladesh, with a competitive cost structure for manufacturing and exporting generic drugs. “This is a combination that is of increasing importance as governments strive to reduce healthcare costs without compromising on quality.”
Nazmul Hassan added: “We look forward to launching further products in Europe, the 2nd largest pharmaceutical market in the world with sales in excess of US$ 265 billion, and providing patients with safe and affordable treatment options.”